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PreviewsFinding the Hematopoietic Stem
Cell Niche in the Placenta
The origin of definitive hematopoiesis poses a funda-
mental biological question. In this issue of Develop-
mental Cell, two groups have independently found a
novel hematopoietic stem cell (HSC) niche in the ex-
traembryonic placenta, in addition to previously iden-
tified alternative locations of hematopoiesis at dif-
ferent developmental stages.
In the majority of vertebrates, the yolk sac serves as
the first site of hematopoiesis and vasculogenensis for
supporting of the developing embryo. The yolk sac is a
bilaminar tissue harboring blood islands that are
formed by clusters of hematopoietic cells surrounded
by a layer of vascular endothelial cells around embry-
onic day 7.5 (E7.5) The yolk sac supports primitive he-
matopoiesis by producing primitive (nucleated) erythro-
blasts, and hematopoiesis moves to other sites later
on within the embryo proper as development proceeds
(Baron, 2003). In contrast, fetal liver-derived HSCs (after
E11) can repopulate the entire hematopoietic system
when transplanted into adults, thus supporting defin-
itive hematopoiesis. As the yolk sac was the only pre-
hepatic site of hematopoiesis identified in early studies,
the colonization theory, which proposed that yolk sac-
derived HSCs colonize fetal liver to initiate definitive he-
matopoiesis and subsequently colonize bone marrow
at the neonatal stages to support adult hematopoiesis,
has been a long-accepted dogma.
In the 1990s, studies of mouse embryos challenged
the colonization theory and located another hematopoi-
esis site in the aorta-gonad-mesonephros (AGM). Actu-
ally, the yolk sac and AGM are both derived from the
mesoderm but segregate during gastrulation into the
extraembryonic mesoderm and the intraembryonic
mesoderm, respectively. The first definitive HSCs can
be detected, in low numbers, in the AGM region after
E10.5. These HSCs are able to repopulate the hemato-
poietic system with multilineage potency when trans-
planted into adult recipients. The AGM region was
therefore assumed to be the source of definitive hema-
topoiesis colonizing the fetal liver (Dzierzak, 2003). Af-
ter E11, the HSCs in fetal liver undergo rapid expan-
sion; however, the number of HSCs in the AGM region
remains low. Thus, the possibility of another source, in
addition to the yolk sac and AGM regions, for definitive
hematopoiesis in the fetal liver (Kumaravelu et al., 2002)
still remained.
In this issue of Developmental Cell, papers by Orkin,
Dzierzak, and their colleagues simultaneously report
that multipotent HSCs can be detected in the placental
labyrinth region during midgestation, thus identifying a
third prehepatic hematopoietic stem cell niche (Gekas
et al., 2005; Ottersbach and Dzierzak, 2005). The pla-cental labyrinth is composed of maternal blood sinus
and fetal capillaries, thus serving as a place for the ex-
change of oxygen and nutrients. Intriguingly, starting at
E10.5-11, there is a parallel appearance of HSCs in
both the placenta and the AGM region. However, the
expansion of the HSC pool size in placenta is much
greater (>15-fold) than that in AGM. Furthermore, the
expansion of the HSC pool size in placenta occurs prior
to and during the expansion of the HSC pool in the fetal
liver but declines toward the end of gestation (E15),
presumably reflecting mobilization of placental HSCs to
the fetal liver. Therefore, the placental HSCs appear to
be the best resource, compared to the yolk sac and
AGM regions, for expansion of the HSC pool in the fetal
liver (Gekas et al., 2005; Ottersbach and Dzierzak,
2005).
A common feature of these three hematopoietic
sites, yolk sac, AGM, and placenta, is that the induction
and generation of hematopoietic cells coincides with
that of endothelial cells. These observations strongly
support that hematopoietic and endothelial cells are
derived from common progenitor cells, hemangioblasts
(Choi, 2002). Indeed, coexpression of endothelial cell
markers CD31/CD34 and hematopoietic stem cell
markers Kit/CD34 (and Sca-1, partially) is found in the
hematopoietic cells in the yolk sac (Yoder et al., 1997),
AGM (North et al., 2002), and placenta (Ottersbach and
Dzierzak, 2005). The origin of hematopoietic and endo-
thelial cells from a common precursor provides an in-
sight into understanding the molecular mechanism that
leads to the induction of hematopoietic lineage fate
during early embryonic development. Flk-1 (encoding
a VEGF receptor) is required for both endothelial and
hematopoietic cell lineage induction (Choi, 2002). The
same is true for Shh signaling through the VEGF/Notch
cascade which is required for both lineages (Gering and
Patient, 2005). Transcription factor SCL is essential for
the induction of hematopoietic, but not endothelial,
cells in the embryo (Choi, 2002). Another important
transcription factor, Runx1 (AML1), plays an important
role in the emergence of HSCs in the AGM region (North
et al., 2002) and is also expressed in the HSCs in the
placenta, implicating a similar role for Runx1 in generat-
ing HSCs in the placenta (Ottersbach and Dzierzak,
2005).
HSCs derived from different sites have different func-
tional capacities. These differences in developmental
potency may result from differences in their inherited
intrinsic programs or may be due to different microenvi-
ronmental signals. Regardless, after coculture with
stromal cells derived from the AGM region (on E10.5),
HSCs from the yolk sac on E8 are able to support defin-
itive hematopoiesis, suggesting that the microenviron-
ment plays a critical role in determining HSC potency
(Matsuoka et al., 2001). Unlike the adult HSC niche,
which imposes a restriction signal for HSC proliferation,
the placenta niche promotes rapid expansion but with-
out inducing myeloerythroid lineage differentiation, and
therefore strongly suggests that the placental labyrinth
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of HSCs. G
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